SiBone (NASDAQ:SIBN – Get Free Report) SVP Michael Pisetsky sold 3,725 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $18.63, for a total transaction of $69,396.75. Following the transaction, the senior vice president directly owned 273,650 shares in the company, valued at $5,098,099.50. This trade represents a 1.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
SiBone Stock Performance
Shares of SIBN opened at $19.48 on Friday. SiBone has a one year low of $11.48 and a one year high of $21.89. The company has a market cap of $863.92 million, a PE ratio of -57.29 and a beta of 0.66. The stock has a 50-day moving average of $17.40 and a 200-day moving average of $15.30. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55.
SiBone (NASDAQ:SIBN – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. On average, equities research analysts predict that SiBone will post -0.4 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Research Report on SiBone
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after purchasing an additional 1,053 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of SiBone during the 1st quarter worth approximately $225,000. Goldman Sachs Group Inc. lifted its position in shares of SiBone by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after buying an additional 83,919 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of SiBone in the 1st quarter worth approximately $1,818,000. Finally, Legal & General Group Plc boosted its stake in shares of SiBone by 16.1% in the 2nd quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock worth $798,000 after buying an additional 5,888 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.
About SiBone
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
Featured Articles
- Five stocks we like better than SiBone
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
